ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Johnson & Johnson's Spravato garners FDA approval for treatment-resistant depression
March 06, 2019The FDA announced the approval of Johnson & Johnson's Spravato (esketamine), in conjunction with an oral antidepressant, for adults with treatment-resistant depression, with the nasal spray only available under a Risk Evaluation and Mitigation Strategy (R
Pharma Sources Insight January 2025
